JP2024532485A - Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 - Google Patents

Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 Download PDF

Info

Publication number
JP2024532485A
JP2024532485A JP2024513933A JP2024513933A JP2024532485A JP 2024532485 A JP2024532485 A JP 2024532485A JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024532485 A JP2024532485 A JP 2024532485A
Authority
JP
Japan
Prior art keywords
seq
binding protein
variable region
chain variable
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532485A5 (https=
Inventor
ペイ，イ
レイ，ミン
ファン，ハイチュン
ロイ，イック
フン チェン，チャン
リ，ハン
Original Assignee
ノヴァロック バイオセラピューティクス， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴァロック バイオセラピューティクス， リミテッド filed Critical ノヴァロック バイオセラピューティクス， リミテッド
Publication of JP2024532485A publication Critical patent/JP2024532485A/ja
Publication of JP2024532485A5 publication Critical patent/JP2024532485A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024513933A 2021-09-03 2022-09-01 Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 Pending JP2024532485A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163240402P 2021-09-03 2021-09-03
US63/240,402 2021-09-03
US202263327700P 2022-04-05 2022-04-05
US63/327,700 2022-04-05
PCT/US2022/075846 WO2023034922A2 (en) 2021-09-03 2022-09-01 Bispecific binding proteins that bind cd137 and a tumor associated antigen

Publications (2)

Publication Number Publication Date
JP2024532485A true JP2024532485A (ja) 2024-09-05
JP2024532485A5 JP2024532485A5 (https=) 2025-09-05

Family

ID=85413134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513933A Pending JP2024532485A (ja) 2021-09-03 2022-09-01 Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質

Country Status (7)

Country Link
US (1) US20240383978A1 (https=)
EP (1) EP4395823A4 (https=)
JP (1) JP2024532485A (https=)
KR (1) KR20240073008A (https=)
AU (1) AU2022337286A1 (https=)
CA (1) CA3230426A1 (https=)
WO (1) WO2023034922A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240133746A (ko) * 2022-01-09 2024-09-04 아이-맵 바이오파마 컴파니 리미티드 다중특이적 작제물 및 이의 용도
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564432A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
EP2303924B1 (en) * 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
EP3554544A4 (en) * 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US20220177583A1 (en) * 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
BR112021008870A2 (pt) * 2019-08-12 2021-11-30 Abl Bio Inc Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
AU2020337958A1 (en) * 2019-08-28 2022-03-17 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
JP7758672B2 (ja) * 2019-12-20 2025-10-22 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
CA3174094A1 (en) * 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
US20250277026A1 (en) * 2021-03-02 2025-09-04 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof

Also Published As

Publication number Publication date
AU2022337286A1 (en) 2024-02-29
CA3230426A1 (en) 2023-03-09
EP4395823A4 (en) 2025-07-16
US20240383978A1 (en) 2024-11-21
EP4395823A2 (en) 2024-07-10
WO2023034922A2 (en) 2023-03-09
KR20240073008A (ko) 2024-05-24
WO2023034922A3 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
US20240383978A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
AU2019264965B2 (en) Antibodies specific to human Nectin4
CN113645996B (zh) 抗claudin 18抗体及其使用方法
JP6432121B2 (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
JP2022504822A (ja) Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
KR20190095941A (ko) 신규 tnfr 효능제 및 이의 용도
WO2022051591A2 (en) Nectin-4 antibodies and uses thereof
US20250277026A1 (en) Antibodies against claudin-6 and uses thereof
US20240067740A1 (en) Antibodies to tnfr2 and uses thereof
CN118234511A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
US20250002599A1 (en) Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof
HK40112412A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
US20260078179A1 (en) Cdh17 antibodies and uses thereof
HK40112413A (zh) 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途
WO2024199364A1 (zh) 抗lag3抗体、药物组合物及用途
CN117425675A (zh) Tnfr2抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250828